These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 5529915)

  • 21. Analysis of deaths in Parkinson patients on long-term levodopa therapy.
    Cote L; Yahr MD; Duvoisin RC; Wolf A; Marksbery W
    Trans Am Neurol Assoc; 1970; 95():73-7. PubMed ID: 4998770
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 24. Aromatic amino acids and modification of parkinsonism.
    Cotzias GC; Van Woert MH; Schiffer LM
    N Engl J Med; 1967 Feb; 276(7):374-9. PubMed ID: 5334614
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 26. Side effects from levodopa.
    Ray I
    Can Med Assoc J; 1972 Jul; 107(1):19. PubMed ID: 5042883
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 28. [Levodopa and Parkinsonism. A double-blind study].
    Pakkenberg H; Dupont E; Garde B; Hansen E; Melsen S; Vestberg F
    Ugeskr Laeger; 1971 Nov; 133(46):2275-9. PubMed ID: 4944650
    [No Abstract]   [Full Text] [Related]  

  • 29. A hort-term evaluation of L-dopa therapy in 34 patients with parkinsonism.
    Mones RJ; Elizan TS
    J Mt Sinai Hosp N Y; 1969; 36(6):503-15. PubMed ID: 5261089
    [No Abstract]   [Full Text] [Related]  

  • 30. Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
    Knopp W
    Neurology; 1970 Dec; 20(12):23-30. PubMed ID: 4924341
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained levodopa therapy in parkinsonism.
    Hunter KR; Shaw KM; Laurence DR; Stern GM
    Lancet; 1973 Oct; 2(7835):929-31. PubMed ID: 4126558
    [No Abstract]   [Full Text] [Related]  

  • 32. Levodopa and induced-pain response. A study of patients with Parkinsonian and pain syndromes.
    Battista AF; Wolff BB
    Arch Intern Med; 1973 Jul; 132(1):70-4. PubMed ID: 4716428
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 34. Gout while receiving levodopa for Parkinsonism.
    Honda H; Gindin RA
    JAMA; 1972 Jan; 219(1):55-7. PubMed ID: 5066588
    [No Abstract]   [Full Text] [Related]  

  • 35. Pilot study with cyclobenzaprine in idiopathic Parkinsonism.
    Korten JJ; van Hemert J
    Psychiatr Neurol Neurochir; 1973; 76(2):119-28. PubMed ID: 4700930
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 37. Levodopa and physical therapy in treatment of patients with Parkinson's disease.
    Stern PH; McDowell F; Miller JM; Robinson M
    Arch Phys Med Rehabil; 1970 May; 51(5):273-7. PubMed ID: 5420013
    [No Abstract]   [Full Text] [Related]  

  • 38. [Our experience with the treatment of Parkinson's disease with L-dopa].
    Buscaino GA; Campanella G
    Acta Neurol (Napoli); 1971; 26(1):46-60. PubMed ID: 5553941
    [No Abstract]   [Full Text] [Related]  

  • 39. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.